CDK4/6-inhibitor or Chemotherapy, in Combination With ENDOcrine Therapy, for Advanced Breast Cancer / KENDO

Metastatic Breast Cancer Clinical Trial

— KENDO  

Official title:

Group Sequential Response Adaptive Randomized Clinical Trial of Concomitant Chemotherapy Plus Endocrine Therapy Versus Cyclin-dependent Kinase 4/6 (CDK4/6) Inhibitor Plus Endocrine Therapy for Advanced Hormone Receptor-positive, HER2-negative Breast Cancer.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03227328
• Other study ID #: IRST174.19
• Secondary ID: 2016-004107-31
• Status: Recruiting
• Phase: Phase 2
• Start date: August 2, 2017
• Est. completion date: July 2022

Study information

• Verified date: April 2020
• Source: Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
• Contact: Oriana Nanni
• Phone: +390543739266
• Email: oriana.nanni[@]irst.emr.it
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Prospective, open label, multicenter, group sequential response adaptive randomized phase 2 study, comparing two treatments for locally advanced or metastatic luminal breast cancer:

• Arm A: concomitant cyclin-dependent Kinase 4/6 (CDK4/6) inhibitor (palbociclib, ribociclib or abemaciclib) plus endocrine therapy (aromatase inhibitor [AI] or fulvestrant)

• Arm B: chemotherapy plus endocrine therapy (AI or fulvestrant, administered either concomitantly from the beginning of chemotherapy or sequentially after 4-6 months of chemotherapy) Treatments will continue until disease progression or toxicity or patient refusal.

Description:

Group sequential response adaptive randomized clinical trial of concomitant chemotherapy plus endocrine therapy versus cyclin-dependent Kinase 4/6 (CDK4/6) inhibitor plus endocrine therapy for advanced hormone receptor-positive, HER2-negative breast cancer Primary Objective: To compare the efficacy of concomitant CDK4/6 inhibitor plus endocrine therapy versus chemotherapy plus endocrine therapy (administered either concomitantly from the beginning or sequentially) in terms of progression-free survival (PFS).

Secondary objectives: To compare between treatment arms:

• quality of life (EORTC quality of life questionnaire(QLQ) QLQ -C30 and QLQ-BR23)

• toxicity (CTCAE version 5.0)

• time to treatment failure

• best response rate

• duration of response

• clinical benefit rate

• overall survival (OS)

• PFS and clinical benefit with the subsequent line of treatment after cross-over: CDK4/6 inhibitors plus endocrine therapy in patients treated with chemotherapy plus endocrine therapy, chemotherapy (with or without endocrine therapy) in patients treated with CDK4/6 inhibitors plus endocrine therapy

• correlative biomarkers of response to CDK4/6 inhibitors and chemotherapy:

• tissue markers (on the primary tumor and / or metastatic tissue)

• circulating markers (e.g. CTCs, ctDNA)

The patients will be allocated according to block randomization until two events are observed in each arm, and then according to the time-to-event adaptation of the group sequential Doubly-adaptive Biased Coin Design (DBCD) whose allocation probabilities are computed at the end of the block randomization and after around 70% and 85% of the 150 maximum patients are enrolled during a 23 month period. At these last two (i.e. after 105 and 128 patients, respectively), interim analysis on efficacy will be carried out allowing for early stopping. At the end of the 16-month follow up, administrative censoring is introduced. Therefore, the total study duration is 39 months.

Previous results on palbociclib and fulvestrant combination in second line and the characteristics of our target population lead us to assume a median PFS of 8 and 12 months for arm A and B, respectively. Under this scenario, for a sample size of at the most 150 patients, the proposed design strategy has led to a simulated power of 0.911 compared with a 0.717 one for the Complete Randomisation design.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 150
• Est. completion date: July 2022
• Est. primary completion date: February 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histological diagnosis of HR-positive (ER =10% of tumor cells), HER2-negative breast cancer, determined by local laboratory on most recent available tumor tissue.

• Locally advanced (not susceptible to locoregional therapy) or metastatic disease (herein globally defined as "advanced breast cancer (ABC)").

• At least one of the following signs of disease aggressiveness:

• The main criteria are a low expression of ER (10% = ER < 50%) and/or a relapse while on the first 2 years of adjuvant endocrine therapy or disease progression (PD) within the first 6 months of first-line endocrine therapy for ABC

• Other tumor characteristics of aggressiveness that make the patient potentially candidate to chemotherapy, according to the guidelines of the Italian Association of Medical Oncology [AIOM guidelines 2017], such as: elevated Ki67 (preferably documented, if available, on a metastatic biopsy), low expression of hormone receptors (e.g. progesterone receptor <20%), extended visceral involvement or visceral involvement at risk for organ failure, uncontrolled symptoms; these patients are eligible if chemotherapy is considered a suitable option by the treating physician.

• Postmenopausal women, or premenopausal women undergoing treatment with LHRH analog, or men (either receiving treatment with LHRH analog or not).

• Measurable disease according to RECIST 1.1 criteria, or not measurable but evaluable disease.

• Any prior adjuvant chemotherapy or endocrine therapy

• No prior chemotherapy for advanced disease.

• Up to one prior line of endocrine therapy for ABC.

• Age = 18 years.

• Eastern Cooperative Oncology Group performance status (ECOG-PS) =2 (see Appendix A).

• Adequate organ (renal, hepatic, bone marrow, cardiac) functions.

• Female participants of child bearing potential and male participants whose partner is of child bearing potential must be willing to use effective contraception during the study period and for 4 months thereafter. Effective contraception methods include: total abstinence (when this is in line with the preferred and usual lifestyle of the subject); tubal ligation; male sterilization; combination of the placement of an intrauterine device or intrauterine system and barrier methods of contraception with spermicidal suppository.

• Participant is willing and able to give informed consent for participation in the study.

Exclusion Criteria:

• Any prior chemotherapy or CDK4/6 inhibitor for advanced breast cancer

• More than 1 prior line of endocrine therapy for ABC.

• Patients who have not recovered from adverse events due to prior therapies to grade =1 (excluding alopecia).

• Active central nervous system metastases.

• History of allergic reactions attributed to compounds of similar chemical or biologic composition to the drugs used in the study.

• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

• Prior history of non-breast malignancy (except for adequately controlled basal cell carcinoma of the skin, carcinoma in situ of the cervix, in situ carcinoma of the bladder), unless treated with curative intent and disease free for at least 3 years.

Related Conditions & MeSH terms

• Breast Neoplasms
• Hormone Receptor Negative Breast Cancer
• Hormone Receptor Positive Breast Cancer
• Metastatic Breast Cancer

Intervention

Drug:
• concomitant cyclin-dependent Kinase 4/6 (CDK4/6) inhibitor plus endocrine therapy
CDK4/6 inhibitor: palbociclib ribociclib abemaciclib Endocrine therapy: non-steroidal or steroidal AI fulvestrant
• chemotherapy plus endocrine therapy (administered either concomitantly or sequentially)
Standard Chemotherapy regimens will be classified as: anthracycline + taxane, taxane, anthracycline, capecitabine / fluoropyrimidines, others. Endocrine therapy: non-steroidal or steroidal AI fulvestrant

Locations

Country	Name	City	State
Italy	A.O.U. Ospedali Riuniti Umberto I - GM Lancisi - G Salesi	Ancona
Italy	U.O. Oncologia Medica; Ist. Tumori Giovanni Paolo II - IRCCS Osp. Oncologico di Bari	Bari
Italy	U.O. Oncologia Medica, P.O. Bellaria-Maggiore	Bologna	BO
Italy	Dip. Medicina Interna e Riabilitazione - U.O. Medicina Interna Oncologica, Ospedale Ramazzini	Carpi	MO
Italy	Terapia Molecolare e Farmaco Genomica, Azienda Socio-Sanitaria Territoriale di Cremona	Cremona
Italy	A.O.U. di Ferrara Arcispedale Sant'Anna	Ferrara
Italy	Ospedale Civile di Guastalla - AUSL di Reggio Emilia	Guastalla
Italy	AUSL Imola	Imola
Italy	Ospedale Mater Salutis - Azienda ULSS9 Scaligera	Legnago
Italy	Ospedale di Macerata, ASUR AV3	Macerata
Italy	UO Oncologia Medica IRST IRCCS	Meldola	FC
Italy	A.O.U. Policlinico di Modena	Modena
Italy	A.O.U. Maggiore della Carità di Novara	Novara
Italy	U.O. Oncologia Medica, AOU di Parma	Parma
Italy	A.O. Santa Maria della Misericordia di Perugia	Perugia
Italy	Dip. Oncologia-Ematologia - U.O. Oncologia Medica,Azienda USL di Piacenza - Ospedale Civile	Piacenza	PC
Italy	UOC Oncologia Medica AUSL Romagna-Ravenna	Ravenna	RA
Italy	A.O. Arcispedale S. Maria Nuova IRCCS di Reggio Emilia	Reggio Emilia
Italy	UO Oncologia Medica AUSL Romagna-Rimini	Rimini	RI
Italy	Ospedale di Sondrio - ASST Valtellina e Alto Lario	Sondrio

Sponsors (2)

Lead Sponsor	Collaborator
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori	Agenzia Italiana del Farmaco

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression Free Survival (PFS)	time from randomization until first disease progression or death; disease progression is defined according to Response Evaluation Criteria In Solid Tumours (RECIST) version 1.1	up to 39 months
Secondary	EORTC QLQ-C30 quality of life between the 2 arms	evaluation of EORTC QLQ-C30 Version 3.0	up to 39 months
Secondary	QLQ-BR23 quality of life between the 2 arms	evaluation of QLQ-BR23 (breast cancer specific)	up to 39 months
Secondary	toxicity	evaluation of toxicity by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0	up to 39 months
Secondary	time to treatment failure (TTF)	the time from randomization to treatment discontinuation for any reason, including disease progression, treatment toxicity, patient refuse or death.	up to 39 months
Secondary	best objective response rate	best objective (partial or complete) response rate according to RECIST 1.1	up to 39 months
Secondary	duration of response	time from documentation of tumor response to disease progression	up to 39 months
Secondary	clinical benefit rate (CBR)	the percentage of patients who achieved complete response, partial response or stable disease lasting longer than 24 weeks	up to 39months
Secondary	overall survival (OS)	time from randomization until death for any cause	up to 39 months
Secondary	Progression free survival (PFS)	PFS and clinical benefit with the subsequent line of treatment after cross-overtime calculated from randomization until the date of start of the subsequent treatment line	up to 39 months
Secondary	correlative biomarkers of response to chemotherapy and endocrine therapy	correlative biomarkers assessed on baseline tumor specimens (from primary tumor or metastatic biopsies) and blood samples collected at baseline and at different timepoints until evidence of disease progression	up to 39 months